Patents Assigned to CDR-LIFE AG
  • Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
    Patent number: 12435444
    Abstract: Rabbit antigen binding protein nucleic acid libraries are provided (e.g., nucleic acid libraries encoding antigen binding proteins that specifically recognize a target peptide-MHC (pMHC)). Methods of producing the rabbit antigen binding protein nucleic acid libraries are also provided.
    Type: Grant
    Filed: March 9, 2022
    Date of Patent: October 7, 2025
    Assignee: CDR-LIFE AG
    Inventors: Anna Maria Sobieraj, Severin Oliver Wendelspiess, Fabian Bert Scheifele
  • Anti-C3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
    Patent number: 12344663
    Abstract: The present invention relates to antibodies and fragments thereof that target the complement C3. More specifically, anti-C3 antibodies and methods of use for the treatment of various diseases or disorders are disclosed.
    Type: Grant
    Filed: December 21, 2022
    Date of Patent: July 1, 2025
    Assignees: CDR-Life AG, Boehringer Ingelheim International GmbH
    Inventors: Leonardo Borras, Pankaj Gupta, Stephanie Jungmichel, Christian Leisner, Philipp Robert Richle, Fabian Scheifele, Anna Sobieraj
  • MAGE-A4 peptide dual T cell engagers
    Patent number: 12161673
    Abstract: Described herein are antigen binding proteins with specificity to Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC). Also described are multispecific antigen binding proteins comprising an antigen binding domain with specificity to CD3, and at least one MAGE-A4 pMHC antigen binding domain. Methods of treating cancer with the same are also described.
    Type: Grant
    Filed: September 13, 2023
    Date of Patent: December 10, 2024
    Assignee: CDR-LIFE AG
    Inventors: Stephanie Jungmichel, Fabian Bert Scheifele, Anna Maria Sobieraj, Philipp Robert Richle, Hannes Merten, Leonardo Borras, Christian Valdemar Vinge Leisner
  • MAGE-A4 peptide-MHC antigen binding proteins
    Patent number: 11912771
    Abstract: Antigen binding proteins that specifically recognize a target Melanoma-Associated Antigen A4 (MAGE-A4) peptide-MHC (pMHC), and nucleic acids encoding the same, are provided. Methods of producing antigen binding proteins that specifically recognize a target MAGE-A4 pMHC, and nucleic acid libraries encoding the same, are also provided.
    Type: Grant
    Filed: March 9, 2022
    Date of Patent: February 27, 2024
    Assignee: CDR-LIFE AG
    Inventors: Anna Maria Sobieraj, Fabian Bert Scheifele, Stephanie Jungmichel, Leonardo Borras, Christian Valdemar Vinge Leisner